Khattab S.,Egyptian International Fertility and Center |
Khattab S.,Cairo University |
Mohsen I.A.,Egyptian International Fertility and Center |
Mohsen I.A.,Cairo University |
And 11 more authors.
Gynecological Endocrinology | Year: 2011
Background.Women with polycystic ovary syndrome (PCOS) are at a high risk to develop Gestational Diabetes mellitus (GDM). We hypothesized that metformin due to its metabolic, endocrine, vascular, and anti-inflammatory effects may reduce the incidence of GDM in PCOS women. Patient and method.We carried out a prospective cohort study to determine the beneficial effects of metformin on PCOS patients during pregnancy. Three-hundred and sixty non-diabetic PCOS patients were included who were conceived on metformin by different treatment modalities. Two-hundred pregnant women continued on metformin at a dose of 10002000mg daily throughout pregnancy (study group) and 160 women discontinued metformin use at the time of conception (control group). Results.There is a statistically significant reduction in the incidence of GDM in favor of metformin group (OR: 0.17, 95% CI: 0.070.37). There is a statistically significant reduction in the incidence of pre-eclampsia in favor of metformin group (OR: 0.35, 95% CI: 0.130.94). Conclusion.Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women. © 2011 Informa UK, Ltd. Source